Epithelial mesenchymal transition (EMT) process has been shown as highly relevant to cancer prognosis. However, although different biological network-based biomarker identification methods have been proposed to predict cancer prognosis, EMT network has not been directly used for this purpose. In this study, we constructed an EMT regulatory network consisting of 87 molecules and tried to select features that are useful for prognosis prediction in Lung Adenocarcinoma (LUAD). To incorporate multiple molecular profiles, we obtained four types of molecular data including mRNA-Seq, copy number alteration (CNA), DNA methylation, and miRNA-Seq data from The Cancer Genome Atlas. The data were mapped to the EMT network in three alternative ways: mRNA-Seq and miRNA-Seq, DNA methylation, and CNA and miRNA-Seq. Each mapping was employed to extract five different sets of features using discretization and network-based biomarker identification methods. Each feature set was then used to predict prognosis with SVM and logistic regression classifiers. We measured the prediction accuracy with AUC and AUPR values using 10 times 10-fold cross validation. For a more comprehensive evaluation, we also measured the prediction accuracies of clinical features, EMT plus clinical features, randomly picked 87 molecules from each data mapping, and using all molecules from each data type. Counter-intuitively, EMT features do not always outperform randomly selected features and the prediction accuracies of the five feature sets are mostly not significantly different. Clinical features are shown to give the highest prediction accuracies. In addition, the prediction accuracies of both EMT features and random features are comparable as using all features (more than 17,000) from each data type.
INTRODUCTION
Accurate prognosis prediction is desirable in cancer clinics because it can stratify patients into different risk groups and assist decision making in treatments [1, 2] .
Traditionally, cancer prognosis predictions are made based on patients' clinical information such as tumor size, TNM stage 1 , age, gender, etc. Nowadays molecular profiles of cancer patients are much easier to obtain. Combining the data with accumulated cancer knowledge, more accurate prognosis prediction could potentially be achieved [3] [4] [5] . The Cancer Genome Atlas (TCGA) offers a comprehensive data portal that contains multiple types of molecular data for more than 30 types of cancer, which enables studies to be carried out such as prognosis prediction [6] , cancer subtypes classification [7, 8] and cancer driver genes identification [8] . This study focuses on the prognosis prediction in lung adenocarcinoma (LUAD) and it is a substantial extension of our previous work [9] .
A few years ago, biomarker identification studies mostly used one data type such as microarray data. Given a high-dimensional dataset, the most informative features (gene expressions) were selected as candidate biomarkers for making predictions [10] [11] [12] . However, it was noticed that there is hardly considerable overlap among biomarkers identified in different studies for the same disease, and biomarkers identified using one dataset may not work well on other datasets [13] . This is largely due to the high dimensionality of the data, which means the size of samples is too small in comparison to the feature size [14, 15] . Therefore there could exist many biomarker options (cohort of selected features) that are equally good, making it difficult to determine the best biomarkers. As it is time-consuming and costly to generate 'enough' samples, to overcome this limitation recent methods advocate the integration of diverse information, such as biological network/pathway and multiple data types, to improve the quality of biomarkers [5, [16] [17] [18] [19] [20] [21] .
Biological networks, typically protein-protein interaction (PPI) networks, are often used to add constraints in feature selection [22] [23] [24] [25] [26] [27] [28] . For example, in [24] the authors employ a combinatorial approach and find groups of genes that are connected in the PPI network and whose expression status together can differentiate patient survival time in glioblastoma multiforme (GBM) cancer.
They achieved 80% classification accuracy using 5 subnetworks each containing 10 genes. In [29] the authors compare the performance of molecular biomarkers and network motif biomarkers in breast cancer prognosis classification. They enumerate all three nodes network motifs using PPI, DNA-protein interaction, and a few pathway databases; assign a score to each motif; and use the scores to make predictions. They show that motif biomarkers achieved higher classification accuracy and reproducibility than individual gene markers. In another study [26] the authors integrate PPI network and gene expression data to identify subnetwork markers for breast cancer metastasis prediction. They find out that subnetwork markers are more reproducible and give more accurate classification prediction.
Besides integrating network information, using multiple molecular data types simultaneously has been proposed to improve prediction accuracy [5] . In [30] , researchers integrated CNA, DNA methylation, gene expression and miRNA expression data in prognosis prediction of GBM and ovarian serous cystadenocarcinoma (OV). They build a graph model for each data type with edges representing similarities among samples, and then integrate the output of the individual graphs. They find out that integrating multiple layers of genomic data can achieve significantly better prediction accuracy. In practice, network-based feature discovery and data integration are not isolated. For example, in [28] , researchers integrate CNA, microarray, patient clinical data and PPI network to identify subnetworks for predicting prognosis of OV. They show that subnetwork biomarkers are able to achieve good prediction accuracy (74.47%) on independent test set and at the same time reveal biologically meaningful pathways.
Encouraged by the studies above, we experimented with mapping multiple types of molecular data to a genetic regulatory network in order to make use of both the network structure and the molecular data. Instead of using the PPI network, we manually constructed an EMT regulatory network [31, 32] by reviewing literature. The network contains genetic regulations and especially miRNA regulations. We chose an EMT network because EMT regulations have been proven as highly relevant to cancer prognosis [33] [34] [35] , which is the target we want to predict. Thus, at the same time we tested whether biologically relevant molecules are good candidate biomarkers for prediction. We obtained LUAD molecular data from the TCGA, including mRNA-Seq, CNA, DNA methylation, and miRNA-Seq data. Then we mapped these different types of data on the EMT network in three alternative ways: mRNA-Seq and miRNA-Seq data, CNA and miRNA-Seq data, and DNA methylation data. For each data mapping five different sets of features, including molecular features as well as subnetwork features, were extracted for prognosis prediction. For a more objective evaluation, we also experimented using randomly picked 87 molecules from each data mapping, using clinical features only, using combinations of molecular features with clinical features, and using all features from each data type.
The results show that clinical features give the most accurate predictions with average AUC value 0.67. Without clinical features, DNA methylation data mapping achieved more accurate predictions that the other two data mappings with average AUC value 0.63. The prediction accuracies of the five different feature sets show significant differences under DNA methylation data mapping but no significant difference under the other two data mappings. Under CNA and miRNA-Seq and DNA methylation data mappings EMT features achieve comparable prediction accuracy as using all features from the corresponding data types. In the following text, we use the word feature(s) in the context of machine learning and the word node(s) in the context of EMT network for clarity.
METHODS
The overall steps of our method are given in the pseudocode below. Detailed explanations of each step are given in the following text.
The Overall Steps
Construct EMT network Obtain and process mRNA-Seq, CNA, DNA Methylation and miRNA-Seq data Map data to the EMT network in 3 alternative ways: mRNA-Seq miRNA-Seq, CNA miRNA-Seq, and DNA Methylation for Each data mapping do Extract five different feature sets for Each feature set do for i = 1 to 10 do Divide the samples into 10 folds for j = 1 to 10 do Apply Lasso feature selection on the data excluding fold j Train SVM or logistic regression classifiers on the data excluding fold j using the selected features Make predictions on fold j end for end for end for end for
Construct EMT Regulatory Network
We reviewed state-of-the-art review papers [31, 32, 36] as well as individual studies [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] on EMT to construct the network to make sure that it includes the key players in EMT regulations. Especially, the network includes non-coding RNA regulations, which have been found in recent years to be associated with EMT [47] . In biological literature the molecules are often referred to as, e.g., the corresponding kinases, transcription factors, or other functional molecules. However, for mapping different types of molecular data to the EMT network, we represent the molecules in the network using the names of their corresponding genes or miRNAs. For example, E-Cadherin, which is an epithelial cell marker, is represented using the name of its coding gene CDH1. Overall, the network has 87 molecules, in which 17 are miRNAs. The names of the molecules are provided in Table 1 . We also visualized the network ( Figure 1 ) using the R package igraph [48] .
Obtain and Process Data
We obtained the following types of data from the FIREHOSE Broad GDAC website (Broad Genome Data Analysis Center [http://gdac.broadinstitute.org]). The data were from TCGA data version 28/01/2016. 2. Level 3 CNA data -copy number alterations for aggregated/segmented regions of chromosomes per sample. It is generated with Affymetrix Genome-Wide Human SNP Array 6.0 platform with Human Genome version 19 (hg19) reference.
Level 3 DNA methylation data -the calculated
Beta-values mapped to the genome per sample. Beta-value is a methylation level measurement of an interrogated CpG site. It is calculated as the ratio of the methylated probe intensity and the sum of methylated and unmethylated probe intensities. The data is additionally preprocessed by calculating the mean Beta-values of the probes among each gene (GDAC Methylation Preprocessor Pipeline).
4. Level 3 miRNA-Seq data -the calculated expression for all reads aligning to miRNAs per sample. The data is generated with Illumina Genome Analyzer miRNA Sequencing platform using RPKM (Reads Per Kilobase exon Model per million mapped reads) quantification.
5. Clinical and follow-up data of patients.
The CNA data we obtained contain the segment mean values of different regions on the chromosomes. To enable the mapping of CNA data to the network, we calculated the gene-level CNA values using the function ProcessCNAData() in the TCGA-Assembler R package [50] . In detail, for each gene on the reference genome hg19, the regions in the CNA data that overlap this gene were found. Then the function takes the sum of the element-wise products of the regions' length and the regions' segment mean values. This value is then divided by the total length of the overlapping regions to give the gene level CNA values. This calculation is performed for every sample to generate gene-level CNA values. In the end, we normalized each of the four data types feature-wise by subtracting the mean and dividing by the standard deviation.
Map Data to the EMT Network
We mapped the data to the EMT network in three alternative ways. The first mapping uses sequencing data including mRNA-Seq and miRNA-Seq data. The second mapping uses CNA and miRNA-Seq data. The third mapping uses DNA methylation data. The reason why we did not use CNA data of miRNAs was that the CNA values of 4 out of 17 miRNAs are missing from the processed data and these four miRNAs have multiple regulatory relations with other nodes in the network.
Feature Engineering
For each data mapping we extracted 5 sets of features using different feature transformation methods based on network-features (NF) and information-discretization (ID) that are grounded on the following motivations. The first one is that network motif structures are associated with biological functions, which has been demonstrated using both biological experiments [51] and modeling and simulation studies [52, 53] . Thus taking network motifs as features could be more robust than taking individual molecules. The second motivation is discretization, which has advantages of removing noise, decreasing computational complexity, and presenting tractable biological interpretations. Although discretization can lose information, it is shown to be effective in a few biological studies such as identifying dysregulated pathways [54] , identifying subnetwork biomarkers [24, 55] , and cancer classification [56] . Based on the two motivations, we included the following feature sets in the experiments:
1. Original EMT molecular features (M original).
The ranking of expression levels of EMT features (M ranking).
It is an ID method. We rank the features within each sample and use the rankings (discrete values from 1 to 87) as the new features. We use ranking because it can reflect the relative abundance of molecules, which associates with cell states and phenotypes.
3. Additive subnetwork features (N additive). It is a NF method. We implemented the subnetwork searching method proposed in [26] . For each subnetwork, the average expression values of its composing nodes were used as the new feature.
Discrete network motif features (N discrete).
It is a NF-ID method. We enumerated all 3-nodes network motifs from the EMT network using Fanmod tool [57] and binarized each feature by its 0.75 quantile. Since there are 3 nodes in each network motif and each node has value either 0 or 1, we can characterize each motif as one feature vector that has only 8 possible states. In this way we transformed the single molecular features to discrete network motif features.
Mutual information weighted network motif features (N miweight).
It is a NF method. We enumerated the network motifs as above and defined the score of each network motif as the weighted sum of the composing molecular features. The weights were decided by the mutual information between each feature and the class label as proposed by [29] .
Feature Selection and Classification
For each data mapping we divided the patients to good prognosis (≥ 1200 days) and poor prognosis (≤ 900 days) groups using right censored patient survival data. We adopted the thresholds by referring to published prognosis prediction studies and by taking into account that the two prognosis classes have relatively balanced sample sizes. The descriptions of the datasets are given in Table 2 . For each data mapping we obtained five datasets corresponding to the above five feature engineering methods. On each dataset we applied feature selection and classification and obtained prediction accuracies using 10 times 10-fold cross validation with three classifiers: SVM with RBF kernel, SVM with linear kernel, and logistic regression. In detail, we applied Lasso feature selection [58] on each training set. The selected features were used to train the classifiers on the training set and we measured the prediction accuracies of the classifiers on the cross validation set. We used the Lasso implementation in glmnet R package [59] and LibSVM [60] implementation in e1071 R package [61] with default settings. We obtained AUC values and AUPR values using pROC R package [62] . Unfortunately, since the number of samples was small we could not create a validation set to adopt for further testing the classifiers independently from the cross-validation. To better evaluate the prediction performance of the EMT molecules, we also applied the same classification methods on the following datasets:
3) randomly picked 87 features from the same and corresponding data types, and the feature sets extracted from it using the EMT network structure. For example, we picked 70 random features from RNA-Seq data and 17 random features from miRNA-Seq data to generate the corresponding 87 random features for the RNASeq miRNASeq data mapping. Then these 87 random features are "mapped" to the EMT network to extract the five feature sets for evaluation.
In terms of statistical tests among multiple groups, we first applied Shapiro-Wilk normality test. If the AUC values of all groups were normally distributed, we used analysis of variance (ANOVA) test and Tukey Honest Significant Differences test (Tukey's HSD test) to determine the differences among the groups. If the AUC values of all groups were not normally distributed, we used Kruskal-Wallis test and Mann-Whitney U test to determine the differences among the groups. We used 95% confidence level in all statistical tests.
RESULTS

Network Visualization
We visualized the EMT network (Figure 1 ) using the Kamada-Kawai layout algorithm [63] from the igraph package. The corresponding molecular regulations in the network are given in Appendix Table 5 . Figure 2 shows the AUC values of the five feature sets using SVM with RBF kernel under each data mapping. Figure 3 shows the comparisons of the AUC values among EMT features, EMT features plus clinical features, randomly picked features, and randomly picked features plus clinical features. Within each data mapping we also show the average AUC values of using all features (blue dotted line) and using only clinical features (red dotted line). The performance of all three classifiers were similar (as shown in Appendix Figure 4 and 5) and we picked the classifier with the highest average AUC values for the plot. Table 3 shows the average AUC values of EMT features and EMT plus clinical features. Figure 2 shows that the five feature sets give slightly different prediction performance under CNA miRNASeq and RNASeq miRNASeq data mappings. Statistical tests show no significant difference.
Prediction Performance
Epithelial Mesenchynal Transition (EMT) Network
DISCUSSIONS
Under DNA Methylation data mapping N miweight feature set gives significantly more accurate predictions than M ranking, N additive and N discrete feature sets. We noticed that network-based features may not outperform the molecular features, which agrees with two other studies [64, 65] . As shown in Table 3 , adding clinical features to EMT features significantly improves the prediction accuracy.
After adding clinical features, all feature sets do not show significant difference in prediction accuracy. Figure 3 shows multiple interesting comparisons. In all cases, the average prediction accuracy of clinical features (the red dotted line) is higher than EMT features and is also higher than using all features of the corresponding data types (the blue dotted lines). Statistical tests show that using EMT plus clinical features (as shown by the purple boxes) in all cases do not achieve significantly better prediction accuracy than using only clinical features. The explanation of this could be that clinical features are the overall reflections of molecular features so that adding molecular features does not increase the prediction accuracy of the model. Figure 3 also shows the comparisons between EMT features (green boxes) and randomly picked features (orange boxes) from the corresponding data types. In contrast to the intuition, EMT features do not always give more accurate predictions than randomly picked features. We think this may be due to the higher correlations among EMT features than the correlations among random features. This brings up the question of why biologically relevant features are not superior predictors for prognosis.
Our opinion is that the biological cause and effect of prognosis could not be properly modeled using SVM and logistic regression classifiers, which are classifiers trained in the original finite-dimensional space or a higher-dimensional space mapped from the original space. Instead, it may be necessary to take into account the molecular regulations within the network since machine learning models could be more useful when the algorithm embodies some domain knowledge or assumptions beyond the data so that the learned model can be generalized on independent data [66, 67] . To avoid the effect of certain randomly picked features on the results, we repeated the experiments three times with different randomly sampled features and obtained similar results.
Therefore, we concluded that clinical features might contain some variables that are influenced by the prognosis of the individual. In fact this is confirmed by the presence of clinical features such as whether the patients had radiation therapy and targeted molecular therapy.
We know that patients receiving these heavy treatments are seriously ill and result in a poor prognosis, hence the prediction obtained by the use of the clinical features could be misleading because of an a-priori association with the patients' prognosis. In addition, we should also address that here we propose the early (and maybe immature) attempt to build an EMT network, which, as a matter of fact, is quite incomplete and of small size. Therefore, the limited performance offered by the EMT derived features most likely can originate by the network incompleteness.
Another interesting finding lies in the comparisons of the prediction performance of using 87 EMT features with using all features. Under RNASeq miRNASeq data mapping, using 20503 RNASeq features does not outperform EMT features. Under CNA miRNASeq data mapping, using 21092 features does not outperform EMT features. Under DNA methylation data mapping, using 17053 methylation features outperformed the M ranking and N discrete features sets but not the rest three feature sets. It seems that although the high-dimensional data provides much more information, it is non-trivial to find the important predictors from it. Table 4 shows that there are high variances in AUC and AUPR values. Under RNASeq miRNASeq data mapping, N additive feature set together with clinical features achieved maximal AUC value of 1, which is perfect classification on the cross validation set. Given that the sample size of cancer omics data is usually limited, it worth further analyzing why some data division gives good prediction accuracy while some data division gives poor performance.
The main contribution of our work is that we for the first time conceived and constructed an EMT regulatory network from state-of-the-art literature, mapped four types of molecular data to the network, and evaluated the prediction accuracies of the extracted features from the network in LUAD prognosis prediction. Our work could provide references for further studies that try to build cancer prognosis predictive models involving EMT regulations.
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